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Abstract
Trop-2 is a transmembrane glycoprotein upregulated in several human carcinomas, including
prostate cancer (PrCa). Trop-2 has been suggested to regulate cell-cell adhesion, given its high
homology with the other member of the Trop family, Trop-1/EpCAM, and its ability to bind the
tight junction proteins claudin-1 and claudin-7. However, a role for Trop-2 in cell adhesion to the
extracellular matrix has never been postulated.
Here, we show for the first time that Trop-2's expression in PrCa cells correlates with their
aggressiveness. Using either shRNA-mediated silencing of Trop-2 in cells that endogenously
express it, or ectopic expression of Trop-2 in cells that do not express it, we show that Trop-2
inhibits PrCa cell adhesion to fibronectin (FN). In contrast, expression of another transmembrane
receptor, αvβ5 integrin, does not affect cell adhesion to this ligand. We find that Trop-2 does not
modulate either protein or activation levels of the prominent FN receptors, β1 integrins; however,
it promotes β1 association with the adaptor molecule RACK1, and causes significant
redistribution of RACK1 to the cell membrane. As a result of Trop-2 expression, we also observe
activation of Src and FAK, known to occur upon β1-RACK1 interaction. These enhanced Src and
FAK activities are not mediated by changes in either the activity of IGF-IR, which is known to
bind RACK1, or IGF-IR's ability to associate with β1 integrins.
In summary, our data demonstrate that the transmembrane receptor Trop-2 is a regulator of PrCa
cell adhesion to FN through the β1 integrin-RACK1-Src-FAK signaling axis.
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Introduction
Integrins are transmembrane receptors for extracellular matrix (ECM) ligands, and are
critical regulators of cell adhesion to ECM (DeRoock et al., 2001; Hynes, 2002; Alam et al.,
§Correspondence to: Lucia R. Languino Ph.D., Department of Cancer Biology, Thomas Jefferson University, 233 South 10th Street,
Philadelphia, PA 19107. Phone: 215.503.3442. Fax: 215.503.1607. lucia.languino@jefferson.edu.
&Current address: Sanofi Pharmaceuticals, Cambridge, MA
The authors state no conflict of interest.
NIH Public Access
Author Manuscript
J Cell Physiol. Author manuscript; available in PMC 2013 November 01.
Published in final edited form as:
J Cell Physiol. 2012 November ; 227(11): 3670–3677. doi:10.1002/jcp.24074.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
2007). Several signaling molecules, including focal adhesion kinase (FAK), Src,
extracellular signal-regulated kinase (ERK) and myosin light-chain kinase (MLCK)
participate in the regulation of dynamic assembly and disassembly of focal adhesions,
macromolecular platforms that contribute to stabilize cell attachment to the substrate
(Kanchanawong et al., 2010). Aberrant integrin signaling, coupled with intensive proteolytic
activity to degrade the surrounding ECM, is frequently detected in several diseases,
including cancer metastasis. Moreover, regulation of the physical link between integrins and
the actin cytoskeleton is critical for the spatio-temporal control of cell detachment from the
substrate, cell migration and metastasis.
Trop-1/EpCAM and Trop-2 are members of a transmembrane glycoprotein family, which is
upregulated in several human carcinomas as compared with their normal counterparts
(Ohmachi et al., 2006; Zanna et al., 2007; Fong et al., 2008; Guerra et al., 2008; Trerotola et
al., 2010). Trop-1 regulates epithelial cell-cell adhesion through homotypic protein-protein
interactions (Balzar et al., 2001; Trebak et al., 2001) and modulates the activity of cadherins
(Litvinov et al., 1997) through PI3K (Winter et al., 2007). Trop-2 is a Ca2+ signal transducer
(Ripani et al., 1998), and has been suggested to resemble Trop-1 in cell-cell adhesion, since
it binds the tight junction proteins claudin-1 and claudin-7 (Nakatsukasa et al., 2010). The
use of Trop-2 for identification and isolation of stem cells in normal and neoplastic prostate
has been reported (Goldstein et al., 2008; Goldstein et al., 2010), suggesting a role for this
molecule in cancer initiation and progression. This is in line with previous literature
correlating Trop-2 expression with poor prognosis in several human carcinomas (Ohmachi
et al., 2006; Fong et al., 2008), and also upregulation during prostate cancer (PrCa)
progression (Calvo et al., 2002).
Signaling pathways previously shown to affect integrin-mediated cell adhesion and
cytoskeletal rearrangements involve a cross-talk between FAK, Src and the receptor for
activated C kinase 1 (RACK1). While FAK and Src have intrinsic kinase activities (Lu et
al., 1997; Marx et al., 2001; Yeatman, 2004; Mitra et al., 2005), RACK1 is an adaptor
molecule known to bind several key signaling proteins, such as activated PKCs (Ron et al.,
1994), FAK (Kiely et al., 2009; Serrels et al., 2010) and Src (Chang et al., 2001). RACK1
activity as regulator of central, stable focal adhesions has been recently reported (Cox et al.,
2003; Serrels et al., 2010), suggesting a critical function of this molecule in cell-ECM
interaction. Focal adhesions bring together cytoskeletal and signalling proteins during the
processes of cell attachment and spreading on ECM, and phosphorylation of FAK is a rapid
event associated with the formation of these adhesive structures (Mitra and Schlaepfer,
2006). Tyr397 is a major autophosphorylation site in FAK, and phosphorylated FAK
promotes binding and activation of Src (Mitra and Schlaepfer, 2006). However, in FAK-null
cells reconstituted with Y397F–FAK or A430V-Src constitutively inactive mutants,
adhesion disassembly is significantly slower than in control cells (Webb et al., 2004),
indicating that an intact FAK-Src signaling axis is critical for inducing disassembly and
turnover of integrin-based adhesion sites, an essential step in the metastatic cascade (Cox et
al., 2006; Natarajan et al., 2006). A complex between RACK1, FAK and the cAMP-
degrading phosphodiesterase PDE4D5 has been recently reported to localize selectively in
nascent focal contacts, rather than in mature adhesions that are formed in cells stably
attached to ECM, and to promote cell polarity (Serrels et al., 2010). It has been shown that
the N-terminal region of RACK1 contains the FAK binding site (Kiely et al., 2009); RACK1
has been also demonstrated to associate with the cytoplasmic domain of several integrins,
among them β1 (Liliental and Chang, 1998; Buensuceso et al., 2001; Besson et al., 2002).
The integrin binding domain of RACK1 is localized in the C-terminal portion; in this region,
the Tyr-246 residue has been identified as a Src binding site (Chang et al., 2001). Finally,
RACK1 has been demonstrated to associate with the Insulin-like Growth Factor I (IGF-I)
receptor (IGF-IR), suggesting a role in the IGF signaling network (Hermanto et al., 2002;
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Kiely et al., 2002). IGF-I and IGF-IR, known to play a positive role in PrCa (Wu et al.,
2006; Zoubeidi et al., 2010), stimulate many signaling pathways upon binding to each other.
Recent reports have shown that IGF-I binding to IGF-IR, which promotes the interaction
between β1 integrins and RACK1 in adherent cells (Kiely et al., 2005), induces
displacement of Src from RACK1 (Kiely et al., 2002); when Src is dissociated from
RACK1, its kinase activity is increased (Cox et al., 2003).
Here, we describe for the first time that Trop-2 inhibits cell adhesion to fibronectin (FN) in
PrCa cells, and we identify the β1 integrin-RACK1-FAK-Src as major signaling axis
involved in this function. This study demonstrates that the transmembrane glycoprotein
Trop-2 is a critical mediator of cell-ECM interaction. We propose that the mechanisms
underlying these events may involve the control of cytoskeletal dynamics and the turnover
of focal adhesions.
Materials and Methods
Reagents and Antibodies
FN – purified from whole blood as described in (Engvall and Ruoslahti, 1977) – and Poly-L-
Lysine (PLL) (Sigma-Aldrich) were diluted in sterile phosphate buffer saline (PBS) for
coating. IGF-I was purchased from R&D Systems. Antibodies (Abs) used for flow
cytometry (FACS) analysis were as follows: mouse monoclonal Ab (mAb) 162.46.2 (ATCC
number: HB-187) against human Trop-2; mouse mAbs TS2/16 (ATCC number: HB-243)
and K20 (M0889, Dako Cytomation), and rat mAb 9EG7 (550531, BD Biosciences), all
against β1 integrins. For immunofluorescence the mAb C20 (610177, BD Transduction
Laboratories) against RACK1 was used. Abs used for immunoprecipitation (IP) were as
follows: mAb against β1 (clone K20), and rabbit polyclonal Ab (pAb) against IGF-IRβ
(C20; sc-713, Santa Cruz Biotechnology). Abs used for immunoblotting (IB) were as
follows: mAbs against β1 integrins (clone C18; 610468, BD Transduction Laboratories),
head domain of talin (talin-H) (clone TA205; MAB1676, Chemicon), RACK1 (C20), and
total Src (clone L4A1, 2110, Cell Signaling); rabbit pAbs against Tyr397 phospho-FAK
(pFAK) (44-624G, Invitrogen), FAK (C-20; sc-558, Santa Cruz Biotechnology), Tyr416
phospho-Src (pSrc) (2101, Cell Signaling), and pY20 (sc-508, Santa Cruz Biotechnology); a
goat pAb against human Trop-2 (R&D Biosystems). Negative control Abs were: purified
non-immune mouse IgG (Pierce/Thermo Fisher Scientific) and purified normal goat IgG
(Santa Cruz Biotechnology).
Cells and Culture Conditions
LNCaP (ATCC) and C4-2B (UroCor, Inc.) cells were cultured in RPMI 1640 medium
supplemented with 5% fetal bovine serum (FBS) (Gemini Bioproducts), 1% non-essential
aminoacids, 1 mM sodium pyruvate, 10 mM Hepes pH 7.3. PC3-1 and PC3-2 are sublines of
the original PC3 line from ATCC, and have been described in (Akech et al., 2010); these
cells were cultured in RPMI 1640 supplemented with 10% FBS. DU145 (ATCC) cells were
cultured in DMEM medium supplemented with 10% FBS.
Constructs and Cell Transfection
The vector for expression of Trop-2 in mammalian cells was pEGFP-N1 from Clontech
(Palo Alto, CA), devoid of the coding sequence of EGFP (pΔEGFP). The human TROP2
cDNA (Fornaro et al., 1995) was amplified by PCR with primers FT2FP
(gcgattctcgagtccggtccgcgttcc – XhoI) and RT2FP (gcgccggtaccaagctcggttcctttc – KpnI) and
subcloned in the pΔEGFP vector. Transfection of PC3-2 and LNCaP cells was performed
with Lipofectamine 2000 reagent (Invitrogen) following manufacturer instructions. Stable
transfectants were selected and maintained in complete RPMI supplemented with G418 (100
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μg/ml). Enrichment for stable transfectants was performed by flow cytometry, using a
fluorescence activated cell sorter (FACSVantage, Becton Dickinson). PC3-2/β5 cells were
generated by transfection of the human β5 integrin cDNA subcloned in the pBABE
retroviral vector, followed by selection with puromycin (0.5 μg/ml). To generate DU145
cells with stable knockdown of endogenous Trop-2, two human Trop-2-directed pLKO.1
lentiviral small hairpin RNA (shRNA) plasmids were obtained from OpenBiosystems (Cat.
n. RHS3979-9623602 and RHS3979-9623605). To generate lentiviral particles, HEK293FT
cells in 6-well plates were co-transfected with 1.85 μg of pLKO.1-Trop-2-shRNA vector,
1.85 μg of pLP1 (gag/pol fusion protein), 0.75 μg of pLP2 (Rev protein) and 0.4 μg of pLP/
VSVG (VSV-G envelope glycoprotein) plasmids using Lipofectamine 2000. Lentivirus-
containing supernatants were harvested 48 h after transfection, followed by filtration
through a 0.45 μm pore diameter filter, and used to infect cultures of DU145 cells. Stably
infected cells were cultured in the presence of 1 μg/ml puromycin for at least one week, and
expression of Trop-2 was analyzed by IB to confirm downregulation. One of the two Trop-2
shRNA plasmids (Open Biosystems Cat. n. RHS3979-9623602) was used as control shRNA
for further experiments since it did not downregulate Trop-2 expression.
Flow Cytometry
Human cell lines and transfectants were subjected to single staining with primary Abs,
followed by fluorescein isothiocyanate (FITC)-conjugated goat anti mouse (GAM)
secondary Abs. Fluorescence intensity was determined by FACS analysis on a FACSCalibur
or a FACS LSRII instrument interfaced with CellQuest Pro software (BD Biosciences).
Activation of β1 integrins in PC3-2 cell transfectants
The β1 integrin activation assay was performed as described (Green et al., 2009). Briefly,
PC3-2/Trop-2, PC3-2/Mock and PC3-2/β5 cell transfectants cultured in complete medium
were washed once with PBS without Ca2+/Mg2+, and cultured for 5 h in serum-free medium.
Cells were then harvested using 1 mM EDTA in PBS without Ca2+/Mg2+. After extensive
washes with PBS without Ca2+/Mg2+, cells were incubated for 30 min in Hepes buffer [20
mM Hepes pH 7.4, 150 mM NaCl, 1% bovine serum albumin, (BSA)]. Hepes buffer devoid
of divalent cations was compared with buffer supplemented with 1 mM CaCl2 / 1mM
MgCl2, or supplemented with 0.2mM MnCl2. Then, cells were incubated for 30 min on ice
in the same buffers described above, in the presence of the Ab K20 to quantify total β1
integrin expression levels, or the Ab 9EG7 to quantify the levels of active β1. A mouse IgG
was used as a negative control Ab.
Generation of Protein Lysates and IB
Protein lysates were prepared by scraping cells in 20 mM Tris-HCl (pH 7.4), 150 mM NaCl,
1mM CaCl2, 1mM MgCl2, 1% NP-40, 1 mM benzamidine, 10 μg/ml leupeptin, 1 mM
phenylmethylsulfonyl fluoride, 1 μg/ml pepstatin A, 1 μM calpain inhibitor, 1 mM Na3VO4,
1 mM Na4O7P2. After 15 min incubation on ice, lysates were centrifuged at 12,000 g for 10
min. Supernatants were collected and protein content was determined using the DC Protein
Assay Kit (Bio-Rad). Samples were subjected to 10% SDS-PAGE under reducing
conditions and transferred onto polyvinylidene difluoride membranes for IB.
Immunoprecipitation
IP experiments were performed as follows: cells were lysed in the lysis buffer described
above and pre-clearing was performed by two consecutive incubations with protein G-
Sepharose at 4°C for 45 min. Binding to the specific Abs (see above) was performed by
incubation at 4°C for 3 h, followed by incubation with protein G-Sepharose for 1 h at 4°C.
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After six washes with lysis buffer, immunocomplexes were separated by reducing SDS-
PAGE.
Activation of IGF-IR in PC3-2 cell transfectants
PC3-2/Trop-2, PC3-2/Mock and PC3-2/β5 cell transfectants were subjected to stimulation
with IGF-I as described (Goel et al., 2004). Briefly, cells were starved in serum-free RPMI
for 24h, then IGF-I was added at 100 ng/ml for 3 min. Cells were lysed as described above,
and IP was performed using an Ab against IGF-IRβ. The immunocomplexes were then
separated by SDS-PAGE and analyzed by IB, using an Ab against phosphorylated tyrosine
residues (pY20) and against IGF-IRβ.
Activation of FAK in PC3-2 cell transfectants
For FAK activation assay, PC3-2 cell transfectants were trypsinized, and trypsin was
inactivated by soybean trypsin inhibitor. After three washes with serum-free RPMI/1%
BSA, cells were maintained in suspension for 30 min at 37°C. Then, cells were seeded on
plastic dishes coated with FN (10 μg/ml) or PLL (1 mg/ml), and incubated for 15 min at
37°C. After two washes with PBS, cells were lysed and separated by reducing SDS-PAGE;
then, IB analysis was performed using an Ab against pFAK (Tyr397) and total FAK.
Cell Adhesion Assay
Coating of plastic surfaces was performed using FN (10 μg/ml) or PLL (1 mg/ml) overnight
at 4°C. Cell adhesion assays were performed as described (Zheng et al., 1999). Briefly, cells
were trypsinized, and trypsin was inactivated by soybean trypsin inhibitor (Roche). After
three washes with serum-free RPMI/1% BSA, cells were counted and seeded on 96-well
plates for 1 h at 37°C. Cells were later fixed with 3.7% paraformaldehyde (PFA) and stained
with 0.1% crystal violet. Cell adhesion was quantified by absorbance at 562 nm using a
microtiter plate reader (ICN Titertek Multiskan Bichromatic). Fisher's exact test was used
for statistical analysis. Each experiment was performed in triplicate. The assays were
repeated at least three times, and similar results were observed.
Immunofluorescence and Confocal Microscopy
Cells were seeded on FN-coated glass coverslips for 1 h at 37°C. Then, fixation with 3.7%
PFA was performed for 15 min at room temperature, followed by quencing with 50 mM
NH4Cl. Cells were permeabilized by incubation with PBS / 0.2% Triton X-100 for 5 min,
and then incubated for 30 min at RT with the blocking solution (PBS / 5% BSA). Staining
was performed incubating samples with the primary mAb to RACK1 for 20 min at room
temperature, followed by incubation with a secondary Ab (Alexa Fluor 488-Rabbit-anti-
mouse) for 20 min at room temperature. After three washes, coverslips were mounted on
glass slides using Pro-Long anti-fade reagent (Invitrogen), and slides were analyzed on an
inverted confocal microscope (LSM510, Carl Zeiss) using Plan-Apochromat 63× (1.4 NA)
or Plan-Neofluar 100× (1.3 NA) lenses.
Results
Trop-2 inhibits cell adhesion to fibronectin
We have previously shown that Trop-2, whose gene is designated TACSTD2 (Fornaro et al.,
1995), is upregulated in human PrCa (Trerotola et al., 2010; Trerotola et al., 2012); this
upregulation is consistent with earlier reports demonstrating increased expression of Trop-2
in a murine model of PrCa progression (Calvo et al., 2002). As depicted in Figure 1, we
extensively analyzed the expression levels of Trop-2 in five human PrCa cell lines. Three
aggressive cell lines: PC3-1 [also designated PC3-H in (Akech et al., 2010)], C4-2B and
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DU145; two less aggressive cell lines: PC3-2 [also designated PC3-L in (Akech et al.,
2010)] and LNCaP. Trop-2 expression is found to be high in aggressive DU145 and PC3-1
cells, intermediate in C4-2B, and undetectable in PC3-2 and LNCaP. Thus, Trop-2's
expression levels may reflect the aggressive phenotype of PrCa cells.
We silenced Trop-2 in DU145 cells using shRNA expressing lentiviruses; in parallel, we
ectopically expressed Trop-2 in PC3-2 and LNCaP cells, as shown by IB (Fig. 2, right
panels). Then, we seeded these cells on FN – a major component of the ECM – in order to
evaluate Trop-2's effect on cell adhesion to extracellular substrates. As shown in Figure 2,
we observe that shRNA-mediated silencing of Trop-2 enhances adhesion of DU145 cells to
FN as compared with parental (157.3 ± 38.6%) and control shRNA cells (77.4 ± 19.3%)
(Fig. 2A, left). Consistently, we observe that ectopic expression of Trop-2 significantly
inhibits adhesion of PC3-2 cells to FN as compared with Mock (55.8±4.8%) or β5
(68.0±4.0%) transfectants (Fig. 2B, left). Since αvβ5 integrin is able to bind FN (Pasqualini
et al., 1993), PC3-2/β5 transfectants were used as a control group in addition to PC3-2/Mock
cells. We also observe that expression of Trop-2 in LNCaP cells inhibits adhesion to FN by
46.6±5.2% as compared with Mock transfectants (Fig. 2C, left). In all cases, BSA was used
as negative control and PLL as loading control.
This experimental evidence indicates that Trop-2 regulates PrCa cell adhesion to FN,
suggesting that its activity may impinge on signaling networks regulated by FN receptors,
namely β1 integrins (Pytela et al., 1985).
Trop-2 does not affect β1 integrin activation
We ruled out the possibility that β1 integrin levels would be altered upon Trop-2 expression
in PC3-2 transfectants. As shown in Figure 3A, we do not detect significant changes in β1
protein levels on the cell surface of PC3-2/Trop-2 transfectants as compared with control
cells. Therefore, we hypothesized that the effect of Trop-2 on cell adhesion to FN might be a
consequence of Trop-2-induced modulation of β1 integrin affinity for FN. A conformational
switch from low-affinity or inactive form to high-affinity or active form occurs upon
integrin binding to their ligands, but can alternatively be induced with activation stimuli
such as Mn2+ ions (Hynes, 2002). This conformational switch exposes CLIBS (cation-and-
ligand-influenced binding site) epitopes that can be recognized by specific antibodies, such
as 9EG7 (Bazzoni et al., 1995). We performed a cation-mediated β1 activation assay by
flow cytometry, using PC3-2 transfectants incubated in the presence of either Ca2+/Mg2+
ions (that do not activate β1) or Mn2+ ions (that do activate β1) (Bazzoni et al., 1995). As
depicted in Figure 3B, we do not observe significant changes of the 9EG7 epitope's levels in
Trop-2 transfectants versus negative controls, indicating that ion-mediated activation of β1
is not affected by Trop-2. Thus, other mechanisms occur to induce the Trop-2-dependent
anti-adhesive phenotype of PrCa cells.
Trop-2 stimulates the association of β1 integrins with RACK1, and the activity of Src
RACK1 is an adaptor molecule that has been previously shown to regulate integrin-
dependent cell adhesion to ECM ligands (Serrels et al., 2010), and to associate with β1
integrins (Liliental and Chang, 1998; Besson et al., 2002). We show that upon ectopic
expression of Trop-2 in PC3-2 cells, the association of RACK1 to β1 integrins is strikingly
enhanced (Fig. 4A), although RACK1's expression levels remain constant (Fig. 4B). We
also performed IP of Trop-2, but we did not detect interaction with RACK1 (data not
shown). We then analyzed the localization of RACK1 in PC3-2 transfectants by
immunofluorescence (Fig. 4C). Our data show that RACK1 accumulates in membrane
compartments in PC3-2/Trop-2 cells, whereas it appears to be diffuse in the cytoplasm of
PC3-2/Mock transfectants (Fig. 4C, left). The percentage of cells in which RACK1 is
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localized in membrane regions was as follows: 82.5±0.9 per cell in PC3-2/Trop-2 (n=140
cells) as compared with 13.1±2.3 per cell in PC3-2/Mock (n=195 cells) transfectants (Figure
4C, right). Thus, these data suggest that Trop-2 induces accumulation of RACK1 in
membrane regions, where this adaptor molecule may form a tight complex with β1 integrins.
Recent reports have shown that IGF-I, required for RACK1 to bind β1 integrins (Kiely et
al., 2005), induces displacement of Src from RACK1 (Kiely et al., 2002) with increase in its
kinase activity (Cox et al., 2003). Therefore, we tested Src activity by immunoblotting using
an Ab specifically targeting the active form of this kinase, pSrc (Tyr416); as depicted in
Figure 4D, we find that the levels of pSrc (Tyr416) are enhanced in PC3-2/Trop-2
transfectants as compared with PC3-2/Mock cells. This appears to be consistent with a role
of Trop-2 as a promoter of β1-RACK1 interaction.
Trop-2 stimulates the phosphorylation of FAK
Adhesion signals and IGF-I promote association between IGF-IR, RACK1 and β1 integrins
(Kiely et al., 2005). Since IGF-IR plays a critical role in the regulation of RACK1's binding
to several partners, we hypothesized that Trop-2 might regulate the activity of IGF-IR, or
alternatively its interaction with β1 integrins (Goel et al., 2004). As shown in Figure 5A, we
observe that IGF-IRβ expression levels are not affected by Trop-2. In addition, we find that
Trop-2 does not alter the activity of IGF-IR. Indeed, when we incubate PC3-2 transfectants
with IGF-I, rapid phosphorylation of IGF-IRβ is detected, independently on Trop-2's
expression (Fig. 5B). Consistently, the association between β1 and IGF-IR was again
unaffected when comparing PC3-2/Trop-2 with PC3-2/Mock and PC3-2/β5 cells (Fig. 5C).
Reduced cell adhesion to ECM substrates occurs through modulation of focal adhesion
turnover, an event affected by FAK, a kinase known to associate with RACK1. Therefore,
we investigated whether Trop-2 affects the activation of FAK in PC3-2 transfectants upon
adhesion to FN. We observe that ectopic expression of Trop-2 induces phosphorylation of
FAK (Tyr397) on FN, whereas reduced levels of phosphorylated FAK (Tyr397) are
observed in PC3-2/Mock and PC3-2/β5 transfectants (Fig. 6A). Thus, Trop-2 promotes an
anti-adhesive phenotype of PrCa cells modulating the β1 integrin-RACK1-FAK-Src
signaling axis.
Discussion
In this study, we demonstrate that Trop-2, a transmembrane protein that is frequently
upregulated in human carcinomas, inhibits PrCa cell adhesion to FN. The mechanism
underlying Trop-2's function in cell adhesion involves modulation of the β1 integrin-
RACK1-FAK-Src signaling axis.
This study describes a function for Trop-2 that has never been demonstrated before, in
inhibiting cell adhesion to FN. This observation is relevant to the understanding of PrCa
mechanisms since Trop-2 expression correlates with, and appears to promote, an aggressive
phenotype of PrCa cells. Since it is conceivable that more aggressive cells need to be poorly
adhesive and more motile than less aggressive cells, we conclude that Trop-2 expression is a
requirement for cancer cells which need to detach from the ECM. Finally, this finding is also
relevant to PrCa since β1 integrins, receptors for FN, are known to be upregulated in this
disease (Goel et al., 2008); thus, we speculate that Trop-2 expression is also required in
distant sites, where FN is upregulated (Ruoslahti, 1999).
The signaling pathway, described here, by which Trop-2 affects PrCa cell adhesion to FN is
also novel for the following reasons. First, it is independent of changes occurring in β1
affinity, as shown by analysis of β1 integrins from a “closed” conformation that does not
allow binding to their ligands to an “open” conformation, resulting in increased affinity for
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the ligands (Hynes, 2002). Second, we demonstrate that Trop-2's effects on PrCa cell
adhesion to FN comprise relocalization of the adaptor molecule RACK1 from cytoplasm to
the cell membrane, and, more importantly, enhanced association between β1 integrins and
RACK1. RACK1 has been reported to bind other integrin β subunits, including β5 (Liliental
and Chang, 1998; Buensuceso et al., 2001); however, ectopic expression of β5 integrin in
PC3-2 cells did not result in significant effects either on cell adhesion to FN or on the β1-
RACK1 binding. This evidence indicates that Trop-2's effect is specific and cannot be
obtained by expression of another transmembrane receptor. Third, Trop-2 does not alter the
association between β1 and IGF-IR, known to occur in PrCa cells (Goel et al., 2004), but its
effect on β1-RACK1 appears to resemble either non-adhesive phenotypes (Kiely et al.,
2005), or the ectopic expression of a defective Y1250/1251F IGF-IR mutant that does not
bind RACK1, which make the β1-RACK1 association constitutive and insensitive to IGF-I
stimulation (Kiely et al., 2005). We thus propose that cells may use Trop-2 to increase the
association between β1 integrins and RACK1 when they need to detach and invade the
surrounding ECM. Finally, the novelty of our observation is that Trop-2 activates a RACK1-
mediated signal from β1 integrin-dependent adhesion to ECM ligands, which converges in
the activation of the motility kinases FAK and Src (Chang et al., 1998; Mitra et al., 2005;
Kiely et al., 2009; Serrels et al., 2010). This is consistent with a previous report showing that
enhanced β1-RACK1 association contributes to activate FAK and Src (Kiely et al., 2005).
Furthermore, additional studies have shown that the N-terminal region of RACK1 contains
the FAK binding site (Kiely et al., 2009), whereas the C-terminal portion of RACK1
mediates interactions with β1 integrins (Liliental and Chang, 1998; Buensuceso et al., 2001;
Besson et al., 2002) as well as Src (Chang et al., 2001). Thus, while FAK is constitutively
associated with RACK1 (Kiely et al., 2009), β1 integrins and Src compete with each other
for binding to the same region. As seen in the schematic model in Figure 6B, we propose
that, as a consequence of Trop-2-mediated increase of the association between RACK1 and
β1, FAK is translocated in close proximity of the β1 cytoplasmic tail. Then, FAK is
autophosphorylated in response to β1 signaling (Mitra and Schlaepfer, 2006), and Src is
released in the cytoplasm and its activity is induced. Increased levels of pFAK (Tyr397)
stimulate binding to active Src, that can further phosphorylate FAK in additional sites, such
as Tyr925, to induce full activation and focal adhesion turnover. The less adhesive
phenotype of PrCa cells observed upon expression of Trop-2 is consistent with earlier
studies showing that a fully-functional FAK-Src pathway is necessary for disassembly and
turnover of focal adhesions, and for a dynamic regulation of cell-ECM interaction (Webb et
al., 2004), one of the earliest steps in the metastatic cascade. FAK has been described to
control microtubule polarization within cells (Palazzo et al., 2004), and this phenotype has
been linked to the cross-talk between FAK and Rho GTPases (Ren et al., 2000). Rac/Rho/
Cdc42 GTPases control formation and disassembly of actin cytoskeletal structures (such as
stress fibers, lamellipodia and filopodia) (Clark et al., 1998; Kuhn et al., 1998; Price et al.,
1998; Hirsch et al., 2002), and support cell motility (Symons and Settleman, 2000). Rho-
family GTPases are also known to promote cell migration (Wells et al., 2010) by activating
p21-activated Ser/Thr kinases (PAK)s (Kumar et al., 2006; Acconcia et al., 2007), which
cross-talk with Src (Siu et al., 2010). Given our evidence that Trop-2 impinges on networks
regulated by FAK/Src, we envision a role for Trop-2 in PrCa cell migration through cross-
talk with these major signaling hubs. Although the pathway described above appears to be
predominant, other important signaling molecules like Pten, Akt (Goswami et al., 2005) and
AR (Lamoureux et al., 2011) are critical for development and progression of PrCa. These
molecules are therefore promising candidates for future investigations of additional
molecular mechanisms underlying Trop-2-mediated events in advanced PrCa.
In summary, we describe a novel molecular mechanism of regulation of PrCa cell adhesion
to FN, whereby the transmembrane glycoprotein Trop-2, previously suggested to have a role
in cell-cell adhesion, modulates cell-ECM attachment by controlling the β1 integrin-RACK1
Trerotola et al. Page 8
J Cell Physiol. Author manuscript; available in PMC 2013 November 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
complex and consequently FAK and Src. Further investigations are needed to delineate
additional roles for Trop-2 in integrin-related functions, such as migration and invasion, and
will allow to develop potential innovative drugs for target therapy of advanced PrCa.
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Fig. 1.
Trop-2 expression in PrCa cell lines. Surface expression profiles of Trop-2 were obtained by
FACS analysis in five human PrCa cell lines: PC3-1, C4-2B, DU145, PC3-2 and LNCaP.
Fluorescence intensity average values up to 103 and over 103 were chosen as thresholds to
designate “intermediate” and “high” expression levels, respectively; “undetectable”
expression was designated for profiles overlapping the ones obtained by staining with a
negative control Ab. Profiles obtained by staining with a mAb to Trop-2, continuous lines.
Profiles obtained by staining with a mouse IgG (negative control Ab), dotted lines.
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Fig. 2.
Trop-2 inhibits cell adhesion to FN. (A) Adhesion assays were performed using DU145/
Trop-2 shRNA cells seeded on FN, PLL and BSA, as described in Materials and Methods.
Parental DU145 cells or DU145/ctr shRNA (infected with a non-silencing shRNA) were
used as negative controls. Error bars, SEM. *, P=0.021. **, P=0.004. Silencing of Trop-2
was evaluated by IB (right panel). FAK, control of protein loading. (B) Adhesion assays
were performed using PC3-2/Trop-2 cell transfectants seeded on FN, PLL and BSA. PC3-2/
Mock and PC3-2/β5 transfectants were used as negative control groups. Error bars, SEM. *,
P=0.0095; **, P=0.0011. Ectopic expression of Trop-2 obtained by transfection of PC3-2
cells was evaluated by IB (right panel). Akt, control of protein loading. (C) Adhesion assays
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were performed using LNCaP/Trop-2 versus LNCaP/Mock transfectants. Error bars, SEM.
*, P=0.030. Ectopic expression of Trop-2 obtained by transfection of LNCaP cells was
evaluated by IB (right panel). FAK, control of protein loading.
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Fig. 3.
Ectopic expression of Trop-2 does not affect either β1 integrin levels or activation. (A) β1
integrin surface levels were analyzed by FACS. Continuous and dotted lines represent β1
integrin surface expression profiles in PC3-2/Trop-2 and PC3-2/Mock cells, respectively.
(B) Activation of β1 integrins was evaluated by FACS analysis on PC3-2/Trop-2 (top
panels) versus PC3-2/Mock (middle panels) and PC3-2/β5 (bottom panels) cells. Continuous
black lines, total β1 integrin expression profiles as measured by staining with K20 Ab.
Dotted black lines, active β1 integrin levels as measured by staining with 9EG7 Ab.
Continuous gray lines, profiles obtained by staining with a negative control Ab. Left
column, β1 integrin expression profiles obtained by incubating cells in a buffer devoid of
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divalent cations. Middle column, β1 integrin expression profiles obtained by incubating cells
in a buffer supplemented with CaCl2 and MgCl2. Right column, β1 integrin expression
profiles obtained by incubating cells in a buffer supplemented with MnCl2.
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Fig. 4.
Trop-2 stimulates the association of β1 integrins with RACK1, and activates Src. (A) β1
integrins were immunoprecipitated using PC3-2 transfectants, and IB was performed on the
immunoprecipitates using an Ab against RACK1. PC3-2/Trop-2 cells were compared with
Mock and β5 integrin transfectants in order to ensure specificity. IB using a mAb against β1
was performed on the same immunoprecipitates as control of loading. (B) Expression levels
of RACK1 were evaluated by IB in PC3-2/Trop-2 versus PC3-2/Mock and PC3-2/β5
transfectants. Talin-H, control of protein loading. (C, left) PC3-2/Mock and PC3-2/Trop-2
transfectants were seeded on FN and analyzed by IF staining with a mAb against RACK1.
High magnification boxed areas (bottom) show membrane regions with specific localization
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of RACK1. Bars, 10 μm. (C, right) The presence of RACK1 in membrane rims was
evaluated. The bar graph indicates the percent fraction of cells showing membrane staining
of RACK1 in PC3-2/Mock versus PC3-2/Trop-2 transfectants. Error bars, SEM. *,
P=0.0092. (D) The activation of Src was analyzed by IB using an Ab against pSrc (Tyr416).
PC3-2/Trop-2 transfectants were compared with PC3-2/Mock. Total Src and FAK, controls
of protein loading.
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Fig. 5.
Trop-2 does not affect either the activity of IGF-IR or its association with β1 integrins. (A)
Expression levels of IGF-IRβ were assessed by IB using PC3-2 transfectants stimulated with
IGF-I for 3 min. (B) IGF-IRβ was immunoprecipitated, and its phosphorylation levels were
assessed by IB using a pY20 Ab. IB using an Ab against IGF-IRβ was performed to confirm
that the receptor was pulled-down from both non-stimulated and IGF-I-stimulated PC3-2
transfectants. (C) The presence of the β1 integrin/IGF-IR complex was investigated in
PC3-2/Trop-2 cells compared with negative control groups by IP of β1 and analysis of IGF-
IRβ by IB.
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Fig. 6.
Trop-2 activates FAK. (A) The activation of FAK was investigated using PC3-2/Trop-2
versus PC3-2/Mock and PC3-2/β5 cells seeded on FN for 10 min. Cells seeded on FN- or
PLL-coated plastic dishes were washed with PBS, lysed and subjected to analysis by IB
using an Ab against pFAK (Tyr397). Total FAK, control of protein loading. (B) Schematic
drawing of Trop-2-mediated inhibition of PrCa cell adhesion to FN through the β1 integrin-
RACK1 signaling axis. (B, left) In cells that do not express Trop-2, RACK1 is mostly
localized in the cytoplasm, where it binds FAK and Src, and prevents Src to be activated; the
functional consequence is a decreased focal adhesion turnover, with stabilized cell adhesion
to FN. (B, right) In Trop-2-expressing cells, increased binding of RACK1 to β1 brings FAK
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in close proximity to β1, and this results in activation of FAK by autophosphorylation of its
Tyr397 residue, release of Src from the complex, and Src activation by phosphorylation of
the Tyr416 residue. Active Src and FAK interact with each other and stimulate downstream
events that finally determine faster turnover of adhesive structures and destabilized cell
attachment to FN.
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